Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy


30 Sep 2019


Poster Display session 3


Tumour Site



Jessica Hassel


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


J.C. Hassel1, C. Berking2, T. Eigentler3, R. Gutzmer4, P.A. Ascierto5, B. Schilling6, F. Hermann7, R. Bartz8, D. Schadendorf9

Author affiliations

  • 1 Section Of Dermato-oncology, Dept Of Dermatology And Nct, University Hospital Heidelberg, 69120 - Heidelberg/DE
  • 2 Dermatology, University Hospital Munich, 80337 - Munich/DE
  • 3 Center For Dermatooncology, Department Of Dermatology, University Hospital Tuebingen, 72072 - Tübingen/DE
  • 4 Department Of Dermatology And Allergy, Skin Cancer Center Hannover, Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, 30449 - Hannover/DE
  • 5 Melanoma, Cancer Immunotherapy And Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 6 Department Of Dermatology, Venereology And Allergology, University Hospital Würzburg, Würzburg/DE
  • 7 Clinical Development, 4SC AG, 82152 - Martinsried (Planegg)/DE
  • 8 Clinical Development, 4SC AG, 82152 - Planegg/DE
  • 9 Department Of Dermatology - Hautklinik, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5545


Many advanced melanoma patients are refractory and do not respond to checkpoint inhibition (CI) alone. Epigenetic modulation of tumors to enhance their immunogenicity, alter the tumor microenvironment and thus increase the chance of response to immunotherapy is one clinical approach. In an open label Phase Ib/II multi-center study (‘SENSITIZE’) we investigated the combination of the HDAC inhibitor domatinostat and pembrolizumab in patients with advanced melanoma.


Advanced stage melanoma patients who were refractory or non-responding to prior checkpoint inhibitor therapy were treated with domatinostat (orally) at increasing dose levels in 3 different dose cohorts in combination with pembrolizumab (2mg/kg) q3w intravenously in a modified “rolling six” study design to evaluate the safety and tolerability of the combination treatment. Tumor assessment was initially performed after 12 weeks. Tumor biopsies were taken for immunohistochemical and gene expression analysis, peripheral blood for PK/PD analysis.


At time of data cut-off on May 8th, 2019 (study ongoing), a total of 23 patients were enrolled into the study. The safety profile indicates that domatinostat-specific adverse events add to the known safety profile of pembrolizumab, but no exacerbation of immune-related adverse events in rate and severity has been observed so far. Domatinostat alone and in combination was considered safe. First signs of efficacy have been observed, including patients one with a partial response and two with stable disease per irRECIST 1.1. Tumor biopsies at baseline showed a domatinostat-induced alteration of the tumor microenvironment including infiltration of CD8+ T cells, the presence of PD-1/ PD-L1 positive cells, and changes on gene expression levels. Furthermore, a dose-dependent PK profile has been observed.


Domatinostat given in combination with pembrolizumab is safe and tolerable and might increase anti-tumor activity in these CI-unresponsive melanoma patients by alteration of the immune tumor microenvironment.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study





P.A. Ascierto: Advisory / Consultancy, Travel / Accommodation / Expenses: 4SC. F. Hermann: Full / Part-time employment: 4SC AG. R. Bartz: Full / Part-time employment: 4SC AG. D. Schadendorf: Advisory / Consultancy, Travel / Accommodation / Expenses: 4SC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.